Table 1

Characteristics of patients with spondylarthritis and rheumatoid arthritis in BIOBADASER and medications used by diagnosis

Total treatments with biologics, n (percentage) by diagnosis


n (percentage) by diagnosis in BIOBADASER

Age*

n (percentage), women

Disease duration*

Infliximab

Etanercept

Adalimumab


Rheumatoid arthritis

4,006 (68.5)

54 ± 13

3,166 (79.0)

10 ± 7

2,789 (60.6)

1,170 (25.4)

577 (12.5)

All spondylarthritis

1,524 (26.0)

45 ± 12

537 (35.2)

10 ± 8

1,180 (70.7)

472 (28.3)

15 (0.9)

Ankylosing spondylitis

657 (11.2)

45 ± 12

152 (23.1)

12 ± 8

570 (80.5)

136 (19.2)

2 (0.3)

Psoriatic arthritis

570 (9.7)

47 ± 12

270 (47.4)

9 ± 7

347 (54.5)

281 (44.1)

9 (1.4)

Undifferentiated spondylarthritis

187 (3.2)

43 ± 12

70 (37.4)

8 ± 7

162 (79.0)

41 (20.0)

2 (1.0)

Crohn's disease arthritis

68 (1.2)

38 ± 13

32 (47.1)

7 ± 8

68 (94.4)

2 (2.8)

1 (1.4)

Juvenile spondylarthritis

19 (0.3)

30 ± 12

7 (36.8)

17 ± 14

17 (89.5)

2 (10.5)

-

Reactive arthritis

12 (0.2)

49 ± 9

2 (16.7)

8 ± 7

10 (83.3)

2 (16.7)

-

Chronic seronegative oligoarthritis

11 (0.2)

35 ± 9

4 (36.4)

4 ± 3

6 (40.0)

8 (53.3)

1 (6.7)


*In years, mean ± standard deviation

p < 0.001 of the difference between rheumatoid arthritis and spondylarthritis as a group.

Carmona et al. Arthritis Research & Therapy 2006 8:R72   doi:10.1186/ar1941

Open Data